1031 GMT - Dassault Systemes' 2029 revenue ambitions are a long way from the French software maker's current performance, analysts at UBS write in a note. Noting the current performance of the company's cloud segment in particular, the analysts expect the group to revise down its revenue guidance at its November capital markets day. However, the company's management remains committed to its earnings per share targets. A turnaround at Medidata, Dassault Systemes' clinical-trial technology division, is key to the company's stock regaining positive momentum, the analysts add. Dassault Systemes shares fall 8.1% after trading was briefly suspended. The stock fell steeply last week after the company issued disappointing guidance. Shares are down over 31% so far this year.(josephmichael.stonor@wsj.com)
(END) Dow Jones Newswires
February 16, 2026 05:39 ET (10:39 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments